Growth Metrics

Amneal Pharmaceuticals (AMRX) Long-Term Deferred Tax (2017 - 2019)

Historic Long-Term Deferred Tax for Amneal Pharmaceuticals (AMRX) over the last 3 years, with Q2 2019 value amounting to $391.9 million.

  • Amneal Pharmaceuticals' Long-Term Deferred Tax rose 486.37% to $391.9 million in Q2 2019 from the same period last year, while for Jun 2019 it was $391.9 million, marking a year-over-year increase of 486.37%. This contributed to the annual value of $373.2 million for FY2018, which is 4145445.43% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Long-Term Deferred Tax stood at $391.9 million for Q2 2019, which was up 486.37% from $382.9 million recorded in Q1 2019.
  • In the past 5 years, Amneal Pharmaceuticals' Long-Term Deferred Tax ranged from a high of $391.9 million in Q2 2019 and a low of $898000.0 during Q4 2017
  • In the last 3 years, Amneal Pharmaceuticals' Long-Term Deferred Tax had a median value of $373.4 million in 2018 and averaged $314.8 million.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first soared by 4145445.43% in 2018, then skyrocketed by 486.37% in 2019.
  • Quarter analysis of 3 years shows Amneal Pharmaceuticals' Long-Term Deferred Tax stood at $898000.0 in 2017, then surged by 41454.45% to $373.2 million in 2018, then rose by 5.02% to $391.9 million in 2019.
  • Its Long-Term Deferred Tax stands at $391.9 million for Q2 2019, versus $382.9 million for Q1 2019 and $373.2 million for Q4 2018.